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Background: Risk communication is an integral part of shared decision-making in health care. In the context of
interventions for chronic diseases it represents a particular challenge for all health practitioners. By using two
different quantitative formats to communicate risk level and effectiveness of a cholesterol-lowering drug, we posed
the research question: how does the format of risk information influence patients’ decisions concerning therapy,
patients’ satisfaction with the communication as well as confidence in the decision. We hypothesise that patients
are less prone to accept therapy when the benefits of long-term intervention are presented in terms of
prolongation of life (POL) in months compared to the absolute risk reduction (ARR). We hypothesise that patients
presented with POL will be more satisfied with the communication and confident in their decision, suggesting
understanding of the time-related term.
Methods/Design: In 2009 a sample of 328 general practitioners (GPs) in the Region of Southern Denmark was
invited to participate in a primary care-based clinical trial among patients making real-life clinical decisions together
with their GP. Interested GPs were cluster-randomised to inform patients about cardiovascular disease (CVD) risk
and the effectiveness of statin therapy using either POL or ARR. The GPs attended a training session before
informing their patients. Before training and after the trial period they received a questionnaire about their attitudes
to risk communication and the use of numerical information. Patients’ redemptions of statin prescriptions will be
registered in a regional prescription database to evaluate a possible association between redemption rates and
effectiveness format. The Combined Outcome Measure for Risk Communication And Treatment Decision Making
Effectiveness (COMRADE) questionnaire will be used to measure patients’ confidence and satisfaction with the risk
communication immediately after the conversation with their GPs.
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Discussion: This randomised clinical trial compares the impact of two effectiveness formats on real-life risk
communication between patients and GPs, including affective patient outcomes and actual choices about
acceptance of therapy. Though we found difficulties in recruiting GPs, according to the study protocol we have
succeeded in engaging sufficient GPs for the trial, enabling us to perform the planned analyses.
Trial registration: ClinicalTrials.gov Protocol Registration System NCT01414751
Keywords: RCT, Shared decision making, Risk communication, Prognosis, Absolute risk reduction, Prolongation of
life, Cardiovascular disease, Primary prevention, Health behaviour, General practiceTable 1 Four different ways of expressing the effect of
preventive cholesterol-lowering therapy to a
hypercholesterolaemic person
Format Examples of ways of expression
RRR If a person with high cholesterol level like you takes the
medicine, the risk of dying from a heart attack will
be reduced by 33% within the next 10 years
ARR If people with high cholesterol level like you do not take
the medicine on average 15 out of 100 people, 15%, will
die of a heart attack within the next 10 years. However,
if people take the medicine on average 10 out of
100, 10%, will die of a heart attack over the next 10 years.
That means that on average 5% fewer persons will die
NNT If 20 people with high cholesterol level like you take the
medicine, there will on average be one more alive
after 10 years than if they do not take the medicine
POL If people with high cholesterol level like you take the
medicine, for the rest of their lives they will on average
live 8 months longer
than if they do not take medicineBackground
In a time when shared decision-making is widely
recommended for clinical practice, risk communication –
an integral component of shared decision-making – has
become an important factor in the doctor-patient encoun-
ter [1-4]. This is especially true for patients confronted
with the risk of a possible future chronic disease such as
cardiovascular disease. Here the decision concerns lifestyle
changes or initiation of long-term preventive medication to
reduce the risk of adverse outcomes. Pharmaceutical
interventions offer well-documented benefits at the
population level. To the individual patient, however,
the immediate clinical effect may be side-effects,
whereas benefits may not be possible to identify or
measure directly. For shared decision-making to be
achieved risk communication is crucial. Effective risk
communication can enhance knowledge, involvement in
decisions about interventions, autonomy and empower-
ment of patients [5]. In contrast, poor communication can
lead to anxiety, lack of confidence in the doctor, and to
decisions based on misinterpreted information and
inadequate communication.
Communicating risk requires skills not always
mastered by patients or doctors alike [6-11]. Skill acqui-
sition is of particular importance when the different nu-
merical presentations of risk are communicated between
doctors and their patients. The standard quantitative ef-
fectiveness formats are
 RRR - relative risk reduction
 ARR - absolute risk reduction
 NNT - number needed to treat
 POL – prolongation of life (or disease-/symptom-
free survival) (Table 1).
Several studies have evaluated these formats in risk
communication and how they can be used in the doctor-
patient encounter [12-16]. The choice of format depends
on various factors, e.g. whether the format is perceived
to be easy to understand; whether it is correctly under-
stood; whether the format meets patients’ information
needs; whether patients receive enough information to
make optimal decisions [17,18]; and how understandingof the format may be affected by factors like age, gender,
or educational level. By presenting risk in different ways,
framing effects may influence how it is perceived [19].
A body of research demonstrates that even when
conveying essentially the same information, patients,
doctors and policy-makers are influenced by differences in
format, including the specific wording and presentation
(e.g. percentages versus natural frequencies) [15,20].
Pictorial representations seem to be better understood
than natural frequencies, and natural frequencies better
than percentages [15]. A Danish study [13] has indicated
that respondents in a survey tend to be more consistent in
their decisions when information is presented in terms of
ARR rather than RRR or NNT. Absolute risk is often used
by GPs when they communicate risk with their patients
and discuss cardiovascular prevention. The GPs often
make use of the Systematic Coronary Risk Assessment
chart (SCORE) [21] or national modified algorithms
[22-26]. The SCORE algorithm calculates a person’s 10-
year statistical risk of fatal cardiovascular disease by means
of the absolute risk in percentages, based on the patient’s
gender, age, smoking status, systolic blood pressure and
total-cholesterol.
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relatively new format of risk reduction. A study of
osteoporosis interventions [27] found that lay people
seem to understand POL in the sense that they were
able to discriminate between different levels of effect-
iveness when presented in terms of disease-free survival
(i.e. “postponement” of hip fracture), but not in terms of
NNT. Similar results have been shown in later studies
[14,28,29]. The studies indicate that the formats
representing the most comprehensible effectiveness may
be ARR and POL. A recent Danish study [30] proposes a
modified algorithm which is based on the same
stratifications as the SCORE model. It presents the
estimated ten-year mortality risk without statin treatment
and the estimated ARR in percentages with treatment, and
with inclusion of non-CVD mortality to provide estimates
of all-cause mortality. Further, the modified algorithm
provides estimates of the remaining life expectancy without
treatment and the POL in months if treated with a statin.
Providing risk and extension estimates with and without
treatment makes it possible to inform patients about
the expected gain on offer. The modified algorithm
(see Additional file 1) forms the basis of the intervention
in the IMPACT trial described in this study protocol.
Many studies on risk communication explore the
conceptual development as to comprehension and
presentation of risk [31] or how lay people, doctors or
policy makers choose treatment in hypothetical situations.
Studies have involved patients [6], but rarely for decisions
about their own therapy. It is therefore unclear how
closely the findings in hypothetical situations accord with
real-life decisions. To the best of our knowledge, no
randomised practice-based studies have yet explored how
real patients’ real-life decisions are influenced by different
risk formats.
Objective and hypotheses
The primary objective of the IMPACT trial was in a
randomised design to explore how risk communication
using ARR versus POL as effectiveness format may affect a
range of endpoints: patients’ decision about redemption of
statin prescriptions, patients’ satisfaction with the commu-
nication in the consultation and patients’ confidence in
their decision. Secondarily, we aimed to study the impact of
teaching the GPs to use the respective effectiveness formats
on GPs’ opinions and experiences in relation to statin
prescribing and risk communication. We chose to use
cholesterol-lowering therapy with statins, as hypercholes-
terolaemia is a well-defined condition, and because statins
as the predominant treatment of hypercholesterolaemia are
used for this condition only, ensuring that prescribed
treatment is used for CVD prevention.
Based on previous research [13,14,27,32] we hy-
pothesise that patients understand POL better thanARR because most people have more experience with
assessment of differences in time than reduced percentages
in risk.
Methods
Design and setting
This cluster-randomised practice-based study has been
implemented among GPs (single-handed or partner-
ship practices) in the Region of Southern Denmark and
their candidate patients for primary CVD prevention
with statins.
Randomisation
Randomisation took place at the level of general
practices and allocated the practices to one of two different
ways of presenting the effectiveness of cholesterol-lowering
therapy. At an afternoon meeting with several practices
gathered, randomisation was based on grouping of doctors
in pairs using geographical location as first criterion, then
type of practice (single-handed or partnership). In each
pair one GP was allocated to ARR, and the other to POL
based on a random-number computer-generated table
prepared before recruitment of general practices.
When visiting individual single-handed practices during
working hours a concealed random-number computer-
generated table with block randomisation of the two
formats in groups of 4 was used for allocation, and an
alternative list used for partnership practices.
Participants
GPs
In August 2009 the Regional Council of Southern
Denmark, provided us with a list of 328 GPs in 13
municipalities in the Region of Southern Denmark
(1.2 million inhabitants). At first we had planned to
invite only GPs from two of the municipalities,
Kolding and Fredericia (a total of 93 GPs), to obtain
the number of practices needed. However, we did not
succeed in recruiting enough GPs, and in October
2009 we consequently decided to invite all GPs on
the list. We invited GPs to participate in a clinical
trial concerning use of quantitative effectiveness
formats in risk communication in health prevention
consultations (typical consultations at which a GP
would review risk factors, levels of risk and potential
benefits of lifestyle or pharmacological interventions
to manage risk). Subsequently, the project manager
(CGH) contacted the GPs by phone and provided further
details about the trial. During this phone call, the GPs
were briefly informed about practicalities if they accepted
to participate.
A total of 30 practices (18 single-handed and 12 partner-
ship practices) were included in the study (Figure 1).
Harmsen et al. BMC Health Services Research 2013, 13:76 Page 4 of 8
http://www.biomedcentral.com/1472-6963/13/76Patients
The GPs have been asked to invite patients to participate
in the trial if the patients have had blood samples taken
for measurement of total-cholesterol and subsequently
returning for a health prevention consultation. Patients
aged 40 to 69 years with a total-cholesterol level above 4
mmol/L (155 mg/dL) will be eligible. This level is in
accordance with Danish national guidelines for prevention
of ischaemic CVD [25]. Patients will be excluded if they
have diabetes, known CVD (including stroke, angina or
myocardial infarction), if they have already received
cholesterol-lowering medication, or if they are not fluent in
Danish. The patients will be informed verbally that the trial
concerns the way GPs communicate risk with their patients
and the patient’s perception of the risk communication.
The patients will receive a written description of the
project including a letter of consent to be signed by the
patient before entering the trial. The GPs will fill out a
specially designed form with information on the individual
patient’s age, gender, systolic blood pressure, total-
cholesterol, and whether the patient consents to participate.
Intervention
The GPs accepting to participate were invited to either a
joint afternoon information meeting or a meeting during
working hours in the GPs’ clinics. The purpose of the
meetings was to instruct the GPs in the use of either ARRWritten invitation to 
Region of Southern
(nclinics=153, nGP
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POL-format (nclinics=15, nGPs=27)
Allocatio
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Figure 1 Flowchart of GP enrolment.or POL. The GPs who attended the afternoon meeting
participated in a two-hour session. The first part of the ses-
sion featured a Power Point presentation by the project
manager (CGH) showing the design of the project. This
was followed by randomisation of the attending GPs (n=7)
to either ARR or POL. The two groups then had separate
information sessions taught by two senior researchers
(both GPs). The GPs were then, based on the randomisa-
tion, instructed to stick to the specifically allocated
effectiveness format when evaluating the measured total-
cholesterol with their patients using specially designed
algorithms for risk assessment (see Additional file 1).
The GPs were told that the focus in the conversation with
their patients should be on total-cholesterol and primary
prevention of hypercholesterolaemia. All GPs who agreed
to participate in the trial were asked to complete a
questionnaire before they began to recruit patients. The
questionnaire consisted of seven items concerning the
individual GP’s preferences and experiences with the use of
quantitative formats when discussing preventive therapies
with their patients, and six items concerning characteristics
of the GP’s practice and workload.
The GPs received a light meal provided by the project
as well as reimbursement for lost income for the time
spent attending the meeting. Additional afternoon
meetings were offered, but not implemented, because
the GPs were either not interested or unable toGPs in the 
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ticipate in an afternoon meeting, were offered a meeting
during working hours in their clinics. These sessions
were conducted by the project manager.
Patients interested in participating in the trial will
receive a questionnaire containing 35 items. The
questionnaire includes a translated version of the
British COMRADE instrument [33-39] consisting of
two subscales. The subscale ‘confidence in decision’
comprises 10 items and focuses on the exchange and
content of information as seen from the patient’s
perspective. The subscale ‘risk communication’ comprises
10 items concerning the emotional evaluation of the
communication. According to proposed guidelines [40-42]
the instrument has been forward-translated from English
into Danish and back-translated into English, and finally
tested for content validity. The remaining items of the
questionnaire concern sociodemographic issues (educa-
tion, household income, marital status), experience with
cardiovascular disease in the patient’s family and self-
rated health. Ideally, the questionnaire is to be answered
immediately after the consultation for the patients to
have a clear memory of the consultation. The patients
are to return the questionnaire in a prepaid envelope
addressed to the research group. Patients who do not
return the questionnaire will receive up to two postal
reminders.
After patient recruitment has ended, we will ask the
GPs to complete a second questionnaire concerning
their experiences with using the agreed quantitative
effectiveness format they have been allocated when
discussing preventive therapies with their patients.Outcomes
The primary outcome measure is patients’ redemptions of
statin prescriptions based on data from Odense University
Pharmaco-Epidemiological Database (OPED) during a
three-month period after inclusion (the day the patient
receives risk information and consents to participate). The
three months will allow for time to consider and adopt
lifestyle changes before initiating cholesterol-lowering
therapy in accordance with Danish guidelines for primary
prevention of CVD [22].
OPED covers all individuals in the Region of Southern
Denmark and captures information on redemption of
reimbursed drugs. Based on the Anatomical Therapeutic
Chemical (ATC) classification [43], OPED has information
on the number of packages and number of Defined Daily
Doses (DDDs) dispensed, prescriber identification, and
date of prescription.
The secondary endpoints are patients’ understanding
of the provided risk information, their perception of
involvement, confidence in the decision made, andsatisfaction with the communication. Here, we will
use the COMRADE instrument [33-39].
Sample size
We based the sample size calculation on expected
redemptions of statin prescriptions in the two groups.
We expected 80% redemption in the ARR group and 60%
in the POL group. This would require 2 groups of each 91
patients to obtain an 80% power with 5% significance in a
non-clustered study. Due to clustering, and assuming an
intra-cluster correlation of 0.1, we estimated a need for a
total of 346 patients for 80% power and 5% significance.
We included some buffer due to possible drop-outs and
ended up with a total of 380 patients expected to be
included by a total of 40 practices.
Statistical methods
We will use descriptive statistics and analyse differences
between groups by means of multilevel logistic and linear
regression modeling, to account for possible clustering
effects. The models will have three nested levels: patient-,
GP-, and practice-level. Regression models will be used to
test for differences between the POL- and the ARR-arm in
patients’ redemption rates and the COMRADE outcomes,
patients’ confidence and satisfaction with communication,
respectively. Three of the COMRADE items focus on
patients’ ease of understanding information, patients’
satisfaction with the information given, and adequacy of
information about issues important for the decision,
respectively. We will conduct separate analyses on each of
these three items. In addition to the explanatory variable
information format (POL versus ARR) we will include
variables which may either be independently associated
with the outcome variable or which have been chosen a
priori from considerations based on expectations and
knowledge within the field. These variables include patients’
baseline risk, patients’ history of angina, impaired
circulation or hypertension, patients’ marital status, age
and gender, GPs’ professional experience (number of years
in general practice), GPs’ prior knowledge of the allocated
format, GPs’ workload, and an affiliation between patient
and GP of more than five years. Missing responses will be
excluded from the analyses.
All analyses will be performed in STATA version 11
(STATACorp, College Station, TX, USA) [44].
Ethical aspects
The trial has been conducted in accordance with Danish
legislation and was approved by the Research Ethics
Committee of the Region of Southern Denmark (project
identification number S-20090034) and reported to the
Danish Data Protection Agency (file number 2009-41
-3208). The trial has been registered at ClinicalTrials.gov
(NCT01414751).
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Summary of objective and design
The objective of the IMPACT trial was in a cluster-
randomised design to compare two different effectiveness
formats, ARR and POL, used in real-life clinical settings in
the risk communication between GPs and patients. Though
there were challenges in the recruitment of GPs, we did
estimate the recruited GPs to be sufficient to include
patients for the trial, and allowing the planned analyses.
Strengths and limitations of the study design
Unlike the majority of trials within the field of risk
communication, this trial is based on real-life patients
making real decisions about interventions to reduce the
risk of a disease, and reflects on real-life consultations.
This implies that we will not know exactly how commu-
nication between the GPs and their patients takes place.
We will not know whether every patient will have the
respective effectiveness format explained; nor can we
rule out selection bias in the GPs’ inclusion of patients.
However, we have chosen a cluster-randomised design,
where the intervention has been randomised at the practice
level rather than at the level of individual patients. By allo-
cating at this level and enabling the individual GPs to use
only one of the effectiveness formats, there will be limited
or no risk of the contaminating effect of the GPs mixing up
the two formats and communicating the wrong informa-
tion to their patients. Further, because the modified algo-
rithm for ARR and POL, respectively [30], has not been
freely available at the time of the study, there has been little
risk of “information contamination” between the GPs.
A limitation may be that only little information will be
collected about the content of the patient-GP encounters,
except for essential characteristics of the patient and GP
concerned. Qualitative interviews may have indicated
issues that we would not be aware of.
We estimated a need for 40 practices to recruit sufficient
patients. However, we had unexpected challenges recruiting
the GPs. Of the 328 GPs, who received written invitations
and follow-up phone-calls, only 30 practices ended up
engaging in the trial. This sparse engagement calls for
reflections as to the risk of performing the study within a
selected group of GPs and limited generalisability.
In the protocol development we had expected that
GPs might be difficult to recruit. First, the workload of
GPs has increased considerably in recent years due to the
transfer of some treatment regimens and follow-ups from
the secondary to the primary level (especially concerning
chronic diseases), and intensified efforts concerning health
promotion. Further, GPs run their practices as private busi-
ness, and time used for engagement in research means less
time for consultations and thus reduced income. Providing
the GPs with fees corresponding to the time spent both on
meetings and patient communication in connection withthe study we aimed at compensating income losses some,
but still recruitment was difficult.
Nevertheless, a considerable number of the GPs,
whether recruited or not, expressed a need for research
in the area of risk communication and development of
tools for use in health prevention consultations.
Implications
With the results of the IMPACT trial we aim to evaluate
the impact of two effectiveness formats on patients’
decision-making concerning primary preventive therapy.
The results may contribute in suggesting how risk
communication in the GP-patient encounter and patients’
satisfaction with the decision-making could be optimised,
if using effectiveness formats when discussing risk and pos-
sible benefits of preventive interventions.
This trial, with a focus on the impact of effectiveness
formats on real patients, will prepare the ground for
future research within the field of risk communication be-
tween health professionals and their patients, and on how
real patients make real decisions. Factors other than ef-
fectiveness information may account for patients’ risk per-
ception and influence patients’ decision-making. An
important issue remaining to be explored within the area
of shared decision-making and primary preventive therapy
is real patients’ perception of risk, both in general and
when concerning their own risk, specifically when
informed about prognosis of disease. It would be particu-
larly important to know how patients’ as well as their GPs’
perception of risk may influence decisions concerning
choice of therapy and adherence in the sense of the ro-
bustness of patients’ decision-making with regard to
whether or not to accept therapy. Knowledge about how
patients and their GPs reflect upon and understand risk in-
formation in relation to making decisions that they would
adhere to could increase cost-effectiveness of treatment, if
appropriate interventions were designed based on such
evidence.
Additional file
Additional file 1: Specially designed algorithms for risk and
effectiveness assessment used in the IMPACT trial. The algorithms
are based on the same stratifications as the SCORE model and present
the estimated ten-year mortality risk and the remaining life expectancy,
respectively, without statin treatment as well as the estimated ARR in
percentages and POL in months, respectively, if treated with a statin.
Participating GPs were allocated and instructed to use only one of the
respective effectiveness formats when informing their patients about CVD
risk and the effectiveness of statin therapy.
Abbreviations
ARR: Absolute risk reduction; ATC: Anatomical Therapeutic Chemical;
COMRADE: Combined Outcome Measure for Risk Communication And
Treatment Decision Making Effectiveness; CVD: Cardiovascular disease;
DDD: Defined daily dose; GP: General practitioner; IMPACT: Influence of
intervention methodologies on patient choice of therapy; NNT: Number
Harmsen et al. BMC Health Services Research 2013, 13:76 Page 7 of 8
http://www.biomedcentral.com/1472-6963/13/76needed to treat; OPED: Odense university pharmaco-epidemiological
database; POL: Prolongation of life; RRR: Relative risk reduction;
SCORE: Systematic coronary risk assessment chart.
Competing interests
The authors declared that they have no competing interest.
Authors’ contributions
CGH contributed to study design and development of intervention. She
drafted the study protocol and coordinates the implementation of the
intervention. HS contributes to the statistics, and together with DEJ, JN, HS,
DGH, JBN, and ISK conceived the idea of the study and developed the
design. AE contributed to the study design, the evaluation and
implementation of COMRADE in a Danish setting. DEJ leads the clinical trial
and contributes to the coordination of the implementation. All authors
contributed to the drafting of the study protocol. All authors read and
approved the final manuscript.
Acknowledgements
We gratefully acknowledge the commitment of the GPs in the Region of
Southern Denmark who approve of the project and help trying out the
effectiveness formats in practice. The study has been funded by The Danish
Research Council, The Danish Heart Foundation (Hjerteforeningen), and The
Committee for Quality and Training of general practitioners in the Region of
Southern Denmark (Kvalitets- og EfteruddannelsesUdvalget i Region
Syddanmark). The sponsors have not been involved in the design or
development of the study.
Author details
1Research Unit of General Practice, University of Southern Denmark, Southern
Denmark, Denmark. 2Department of Public Health, Biostatistics, Aarhus
University, Aarhus, Denmark. 3Institute of Public Health, University of
Southern Denmark, Southern Denmark, Denmark. 4Cochrane Institute of
Primary Care & Public Health, School of Medicine, Cardiff University, Wales,
UK. 5Department of Health Management and Health Economics, University
of Oslo, Oslo, Norway.
Received: 9 January 2013 Accepted: 14 February 2013
Published: 25 February 2013
References
1. Charles C, Gafni A, Whelan T: Shared decision-making in the medical
encounter: what does it mean? (or it takes at least two to tango). Soc Sci
Med 1997, 44:681–692.
2. Edwards A, Elwyn G, Wood F, Atwell C, Prior L, Houston H: Shared decision
making and risk communication in practice: a qualitative study of GPs’
experiences. Br J Gen Pract 2005, 55:6–13.
3. Elwyn G, Edwards A, Kinnersley P, Grol R: Shared decision making and the
concept of equipoise: the competences of involving patients in
healthcare choices. Br J Gen Pract 2000, 50:892–899.
4. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P,
Cording E, Tomson D, Dodd C, Rollnick S, et al: Shared decision making: a
model for clinical practice. J Gen Intern Med 2012, 27:1361–1367.
5. Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, Bloor M,
Burnard P, Covey J, Pill R, et al: The effectiveness of one-to-one risk
communication interventions in health care: a systematic review. Med
Decis Making 2000, 20:290–297.
6. Sheridan SL, Pignone M, Lewis CL: A randomized comparison of patients’
understanding of number needed to treat and other common risk
reduction formats. J Gen Int Med 2003, 18:884–892.
7. Kristiansen IS, Nexoe J, Gyrd-Hansen D, Nielsen JB: NNT is not easily
understood. Fam Pract 2002, 19:566–567.
8. Halvorsen PA, Kristiansen IS: Decisions on drug therapies by numbers
needed to treat: a randomized trial. Arch Intern Med 2005, 165:1140–1146.
9. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB: Laypersons’
understanding of relative risk reductions: randomised cross-sectional
study. BMC Med Inform Decis Mak 2008, 8:31.
10. Halvorsen PA, Kristiansen IS, Aasland OG, Forde OH: Medical doctors’
perception of the “number needed to treat” (NNT). A survey of doctors’
recommendations for two therapies with different NNT. Scand J Prim
Health Care 2003, 21:162–166.11. Nexoe J, Gyrd-Hansen D, Kragstrup J, Kristiansen IS, Nielsen JB: Danish GPs’
perception of disease risk and benefit of prevention. Fam Pract 2002,
19:3–6.
12. Edwards A, Elwyn G, Mulley A: Explaining risks: turning numerical data
into meaningful pictures. BMJ 2002, 324:827–830.
13. Stovring H, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB:
Communicating effectiveness of intervention for chronic diseases: what
single format can replace comprehensive information? BMC Med Inform
Decis Mak 2008, 8:25.
14. Dahl R, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB: Can postponement
of an adverse outcome be used to present risk reductions to a lay
audience? A population survey. BMC Med Inform Decis Mak 2007, 7:8.
15. Gigerenzer G, Edwards A: Simple tools for understanding risks: from
innumeracy to insight. BMJ 2003, 327:741–744.
16. Kristiansen IS, Gyrd-Hansen D: Communicating treatment effectiveness in
the context of chronic disease processes. Expert Rev Pharmacoecon
Outcomes Res 2006, 6:673–679.
17. O’Connor AM, Stacey D, Entwistle V, Llewellyn-Thomas H, Rovner D,
Holmes-Rovner M, Tait V, Tetroe J, Fiset V, Barry M, et al: Decision aids for
people facing health treatment or screening decisions. Cochrane
Database Syst Rev 2003, CD001431.
18. Sepucha K, Ozanne E, Silvia K, Partridge A, Mulley AG Jr: An approach to
measuring the quality of breast cancer decisions. Patient Educ Couns
2007, 65:261–269.
19. Edwards A, Elwyn G, Covey J, Matthews E, Pill R: Presenting risk
information–a review of the effects of “framing” and other
manipulations on patient outcomes. J Health Commun 2001, 6:61–82.
20. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S:
Helping doctors and patients make sense of health statistics.
Psychological Science in the Public Interest 2007, 8:53–96.
21. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, De BD,
Ducimetiere P, Jousilahti P, Keil U: Estimation of ten-year risk of fatal
cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003,
24:987–1003.
22. Christensen B, Faergemann O, Heeboll-Nielsen NC, Lous J, Madsen LD,
Stender S: Prevention of ischaemic cardiovascular disease in general
practice. A clinical guideline [In Danish]. 3rd edition. Copenhagen: The
Danish College of General Practitioners; 2007:1–56.
23. Meland E, Ellekjaer H, Gjelsvik B, Kimsas A, Holmen J, Hetlevik I:
Pharmacological prevention of cardiovascular diseases in general
practice [In Norwegian English summary]. Tidsskr Nor Laegeforen 2000,
120:2643–2647.
24. Norheim OF, Gjelsvik B, Kjeldsen SE, Klemsdal TO, Madsen S, Meland E,
Narvesen S, Negard A, Njolstad I, Tonstad S, et al: National guidelines for
individual primary prevention of cardiovascular disease [In Norwegian].
Oslo: Norwegian Directorate of Health; 2009:2–137.
25. Thomsen T, Christensen B, Hildebrandt P, Iversen HK, Larsen ML, Sillesen H,
Snorgaard O, Videbæk L: Clinical guidelines for prevention of
cardiovascular disease in Denmark [In Danish]. Copenhagen: Danish
Society of Cardiology; 2004:1–16.
26. van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM: Evaluation
of cardiovascular risk predicted by different SCORE equations: the
Netherlands as an example. Eur J Cardiovasc Prev Rehabil 2010,
17:244–249.
27. Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS: A
randomized trial of laypersons’ perception of the benefit of osteoporosis
therapy: Number needed to treat versus postponement of hip fracture.
Clin Ther 2003, 25:2575–2585.
28. Halvorsen PA, Selmer R, Kristiansen IS: Different ways to describe the
benefits of risk-reducing treatments: a randomized trial. Ann Intern Med
2007, 146:848–856.
29. Halvorsen PA, Wisloff TF, Stovring H, Aasland O, Kristiansen IS: Therapeutic
decisions by number needed to treat and survival gains: a cross-
sectional survey of lipid-lowering drug recommendations. Br J Gen Pract
2011, 61:e477–e483.
30. Stovring H, Harmsen CG, Wisloff T, Jarbol DE, Nexoe J, Nielsen JB, Kristiansen
IS: A competing risk approach for the European Heart SCORE model
based on cause-specific and all-cause mortality. Eur J Prev Cardiol 2012.
Epub ahead of print.
31. Woloshin S, Schwartz LM: How can we help people make sense of
medical data? Eff Clin Pract 1999, 2:176–183.
Harmsen et al. BMC Health Services Research 2013, 13:76 Page 8 of 8
http://www.biomedcentral.com/1472-6963/13/7632. Gyrd-Hansen D, Halvorsen P, Nexoe J, Nielsen J, Stovring H, Kristiansen I:
Joint and separate evaluation of risk reduction: impact on sensitivity to
risk reduction magnitude in the context of 4 different risk information
formats. Med Decis Making 2011, 31:E1–E10.
33. Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M,
Kinnersley P, Houston H, Russell I: The development of COMRADE–a
patient-based outcome measure to evaluate the effectiveness of risk
communication and treatment decision making in consultations. Patient
Educ Couns 2003, 50:311–322.
34. Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P,
Russell I: Patient-based outcome results from a cluster randomized trial
of shared decision making skill development and use of risk
communication aids in general practice. Fam Pract 2004, 21:347–354.
35. Martin RW, Head AJ, Rene J, Swartz TJ, Fiechtner JJ, McIntosh BA, Holmes-
Rovner M: Patient decision-making related to antirheumatic drugs in
rheumatoid arthritis: the importance of patient trust of physician.
J Rheumatol 2008, 35:618–624.
36. Wetzels R, Wensing M, van WC, Grol R: A consultation leaflet to improve
an older patient’s involvement in general practice care: a randomized
trial. Health Expect 2005, 8:286–294.
37. Edwards A, Elwyn G: How should effectiveness of risk communication to
aid patients’ decisions be judged? A review of the literature. Med Decis
Making 1999, 19:428–434.
38. Edwards A, Elwyn G, Smith C, Williams S, Thornton H: Consumers’ views of
quality in the consultation and their relevance to ‘shared decision-
making’ approaches. Health Expect 2001, 4:151–161.
39. Llewellyn-Thomas HA: Patients’ health-care decision making: a framework
for descriptive and experimental investigations. Med Decis Making 1995,
15:101–106.
40. Beaton DE, Bombardier C, Guillemin F, Ferraz MB: Guidelines for the
process of cross-cultural adaptation of self-report measures. Spine
(Phila Pa 1976) 2000, 25:3186–3191.
41. Guillemin F, Bombardier C, Beaton D: Cross-cultural adaptation of health-
related quality of life measures: literature review and proposed
guidelines. J Clin Epidemiol 1993, 46:1417–1432.
42. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson
P: Principles of Good Practice for the Translation and Cultural Adaptation
Process for Patient-Reported Outcomes (PRO) Measures: report of the
ISPOR Task Force for Translation and Cultural Adaptation. Value Health
2005, 8:94–104.
43. WHO Collaborating Centre for Drug Statistics Methodology: ATC classification
index with DDDs. Oslo: Norwegian Institute of Public Health; 2013.
44. StataCorp: Stata Statistical Software: Release 11.1. StataCorp LP; 2009.
doi:10.1186/1472-6963-13-76
Cite this article as: Harmsen et al.: Impact of effectiveness information
format on patient choice of therapy and satisfaction with decisions
about chronic disease medication: the "Influence of intervention
Methodologies on Patient Choice of Therapy (IMPACT)"
cluster-randomised trial in general practice. BMC Health Services Research
2013 13:76.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
